Before its fifty percent surge, the drug giant was repeatedly telling a story about its future that the market seemed to be ...

While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's ...

Merck remains in focus after important pipeline developments, new product approvals, and clinical progress strengthen ...

Merck looks like a buy-the-dip at $114.90 with a 3% yield and 12x forward P/E. Click here to read more on the MRK stock.

Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than ...

Merck remains in focus as combination therapy development and pipeline progress shape the broader healthcare landscape.

Merck’s MRK stock climbed above its 50-day SMA from early June after trading below it for most of May. However, the stock has ...

Merck & Co., Inc. (NYSE:MRK) is included among the Billionaire Ken Fisher’s Top 11 Dividend Stock Picks. Reuters reported on ...

Rahway, New Jersey-based Merck & Co., Inc. (MRK) is an international healthcare company that offers human health ...